Navigation Links
Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD)
Date:5/15/2008

GREEN BAY, Wis., May 15 /PRNewswire/ -- Omega 3 fatty acids bound to phospholipids deserves to be further considered as a credible natural alternative and may have beneficial effect on impulsivity in ADHD patients, recent in vivo French study reveals. While several studies have reported beneficial effects of omega-3 in hyperactivity, French researchers have hypothesized that Vectomega(R) could have specific positive effects on impulse control.

These research findings have led to the initiation of two multi-center studies currently underway in France and Germany utilizing Vectomega(R) on hyperactive children. Vectomega(R), a natural whole food Omega 3 fatty acid bound to phospholipids and peptides, is the end result of a French governmental research project.

In 2001, the French government solicited researchers throughout France to investigate potential uses of omega 3 fatty acids and phospholipids. Vectomega(R) is an extract of marine phospholipids complexed with EPA and DHA from salmon heads, the result of the research work by three, world-renowned scientists in the field of phospholipids and essential fatty acids, Professor Michel Linder, Professor Jacques Fanni, and Professor Michel Parmentier. Professor Linder will visit the United States to present at the 99th Annual AOCS Meeting to be held in Seattle May 18-21, 2008.

Vectomega(R), distributed exclusively in the United States by EuroPharma Inc, is a whole food omega-3 EPA/DHA complex which includes phospholipids and marine peptides as they naturally occur in salmon. Molecularly different from other omega-3's on the market, Vectomega(R) is said to be up to 10 to 50 times more absorbable across cellular membranes, using Caco-2 analysis, than other EPA/DHA products.

Vectomega(R) is extracted using a patented enzymatic and pure water innovation that extracts naturally occurring marine phospholipids with the omega-3 fatty acids, EPA and DHA. The extraction is carried out in less than an hour in an inert atmosphere at a temperature lower than 60 degrees C. The omega 3 fatty acids, EPA and DHA can be extracted maintaining their position on the triglyceride chain using this patented process and keeping their natural proportions and composition. This patented innovation, called vectorization, uses a gentle, cold water and enzyme process avoiding heat, solvents, and chemical modifications that are utilized to process all other fish oils. This patented process provides an excellent advantage for the consumer, as the finished phospholipid complex is in tablet form, requiring only one tablet per day, with no regurgitation or fishy after-taste.

"Omega 3 oils containing EPA/DHA have become increasingly popular in response to the growing body of science that validates their numerous health benefits, including heart health and cognitive function," stated Terry Lemerond, president of EuroPharma. "Vectomega(R) surpasses all other EPA/DHA products in terms of bioavailability, absorption and efficacy. Much of the value is lost in fish oils currently on the market because they are highly refined, distilled and deodorized by the use of extraction processes that use high temperatures, solvents and chemical modifications. Vectomega(R) is the only whole food omega 3 complex that is extracted from salmon in a natural process," said Lemerond.

Prevalence estimates of ADHD diagnosis in US school-aged children is 7.4% (4.7 million children) according to the CDC website. The nutritional supplement omega 3 category is reported to be a $7 billion dollar market. The vast benefits of omega 3 supplementation are widely studied and recognized by the media and consumers.

EuroPharma, Inc. a Green Bay, Wisconsin-based nutritional supplement supplier offering a full line of dietary supplements to health food stores, doctors and natural pharmacies throughout the US. EuroPharma's president, Terry Lemerond has over 40 years of industry experience and product development expertise and is the recipient of the 2008 Natural Products Association Industry Champion Award. The Natural Products Association Industry Champion Award recognizes individuals who have made notable contributions to the natural products industry above and beyond commercial success. For more information on Vectomega(R) or EuroPharma(R), please contact Lisa Joski at Ljoski@EuroPharmaUSA.com, 920-406-6506, or visit http://www.EuroPharmaUSA.com.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pregnant Women Need Omega-3 to Boost Infant Development
2. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
3. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
4. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
7. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
8. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):